Login
$RCUS
$16.86 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role Joined Source
Terry Rosen, Ph.D. Also a director
Chief Executive Officer, Director and Chairman
66 Not stated Not stated
Robert C. Goeltz, II
Chief Financial Officer
53 Since 2020
6 years
Not stated
Juan Carlos Jaen, Ph.D.
President
68 Since 2015
11 years
Not stated
Richard Markus, M.D., Ph.D.
Chief Medical Officer
60 Since 2025
1 year
2025
Carolyn Tang
General Counsel
47 Since 2019
7 years
2017
Alexander Azoy
Chief Accounting Officer
Title from the Form 4 dated Aug 21, 2026
Not stated Not stated Not stated

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
11
serving now
Independent
6 of 10
stated in the proxy; 1 not stated
Average tenure
6.4 years
from year joined
CEO also chairs the board
Yes
Terry Rosen, Ph.D. III
Director Age On board Independent Committees Other public boards 2025 pay Source
Terry Rosen, Ph.D. III
66 2015
11 years
Not independent None stated IDEAYA Biosciences, Inc. Paid as CEO
Dietmar Berger, M.D., Ph.D.
63 2025
1 year
Not independent
Science
None stated Not stated
Kathryn Falberg
65 2017
9 years
Independent
Audit · Chair
Nuvation Bio Inc. $468,834
Linda Higgins, Ph.D.
63 2021
5 years
Not independent
Science
Galapagos NV Not stated
Yasunori Kaneko, M.D.
72 2015
11 years
Independent
Audit
None stated $500,331
David Lacey, M.D.
73 2020
6 years
Independent
Compensation Science
Nurix, Inc. $563,764
Nicole Lambert
52 2021
5 years
Independent
Nominating and Corporate Governance
None stated $461,251
Patrick Machado, J.D.
62 2019
7 years
Not stated
Nominating and Corporate Governance
Xenon Pharmaceuticals, Alumis Inc $455,042
Andrew Perlman, M.D., Ph.D.
78 2020
6 years
Independent
Audit
None stated $472,542
Antoni Ribas, M.D., Ph.D.
60 2019
7 years
Independent
Science
None stated $521,264
Johanna Mercier
56 2024
2 years
Not independent None stated Neurocrine Biosciences, Inc. Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

6 disclosed in the proxy filed Apr 21, 2026
Gilead Sciences, Inc.
beneficial holder of more than 5% of our capital stock
Amount not stated

Option, License and Collaboration Agreement entered into in 2020, giving Gilead an exclusive license to the anti-PD-1 program and option rights to clinical programs, with cost-sharing and royalties.

Gilead Sciences, Inc.
beneficial holder of more than 5% of our capital stock
Amount not stated

Investor Rights Agreement entered into in 2020, under which Gilead designated three individuals to the board of directors and a Science Committee was established.

Gilead Sciences, Inc.
beneficial holder of more than 5% of our capital stock
$15 million
February 2025

Gilead acquired shares in the company's February 2025 underwritten equity offering from the underwriters.

Son of Terry Rosen, Ph.D.
son of Terry Rosen, Ph.D., our Chief Executive Officer and member of the Board
Approximately $259,000
2025

Employment of a son of the CEO as Director in the chemistry department, with 2025 cash compensation, option and restricted stock unit grants.

Another son of Dr. Rosen
son of Terry Rosen, Ph.D., our Chief Executive Officer and member of the Board
Approximately $217,000
2025

Employment of another son of the CEO as Principal Investigator in the biology department, with 2025 cash compensation, option and restricted stock unit grants.

Daughter-in-law of Dr. Rosen
daughter-in-law of Dr. Rosen
Approximately $193,000
2025

Employment of the CEO's daughter-in-law as Principal Investigator in the bioinformatics department, with 2025 cash compensation, option and restricted stock unit grants.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support